Navigation Links
AstraZeneca to Support Drug-Induced Liver Injury Network at the National Institutes of Health
Date:5/27/2010

BETHESDA, Md., May 27 /PRNewswire/ -- A new public-private partnership between AstraZeneca and NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will focus on supporting the work of the Drug-Induced Liver Injury Network (DILIN).  DILIN is a group working to bring together essential scientific and financial resources to better understand drug-induce liver injury as well as effective screening, diagnostic and treatment options.  

Drug-induced liver injury, whether caused by prescription or non-prescription medication, is the most common cause of acute liver failure in the United States. It is the major reason for non-approval, withdrawal and limiting the prescribing of medications by the Food and Drug Administration.

Under the terms of the partnership, AstraZeneca will join other companies to provide funding for the project.  AstraZeneca will also have a seat on a DILIN scientific board, a group convened by FNIH that includes representatives of all the partners in this endeavor, to provide expertise and input on scientific and technical matters.  No details of the financial support were disclosed.  

"AstraZeneca is keen to support this important project to help the industry and the medical community better understand and mitigate the risks of liver damage associated with the use of some medicines," said Joachim Forsgren, VP and Global Head of Patient Safety at AstraZeneca.  "The safety of patients who need drugs to treat many different kinds of conditions and illnesses is paramount in both developing new medicines and safely and effectively using products currently on the market. We want to play our part in furthering this critical work, which will provide valuable insight to all those engaged in the research and development of drugs."

"We welcome the support of AstraZeneca's underlying commitment to work with the Foundation for NIH, and NIH, as we pursue advances in research and potential treatment options for drug-induced liver injury. Bringing together a team of experts in a collaborative environment is essential to this project's overall success," said Foundation for NIH Chairman, Charles A. Sanders, M.D.  

NIDDK launched the Drug-Induced Liver Injury Network in 2004 to address this increasingly frequent health problem, The network gathers clinical information and biological specimens in cases of suspected liver injury due to drug and/or herbal remedy use and promotes research on the underlying causes, means of prevention, and approaches to management and therapy.

NOTES TO EDITORS:

Foundation for NIH.   For additional information about the Foundation for NIH, please visit www.fnih.org.

Established by the United States Congress to support the mission of the NIH—improving health through scientific discovery in the search for cures—the Foundation for NIH is a leader in identifying and addressing complex scientific and health issues. The foundation is a non-profit, 501(c)(3) corporation, which raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities.

NIDDK. For more information, please visit www.niddk.nih.gov.

DILIN. Additional details on DILIN are available at the project website, https://dilin.dcri.duke.edu/.

About AstraZeneca.  For more information, please visit: www.astrazeneca.com.


'/>"/>
SOURCE Foundation for the National Institutes of Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
2. Remarks as Prepared for Delivery By Attorney General Eric Holder at the AstraZeneca Settlement Announcement
3. Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing
4. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
5. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
6. AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
7. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
8. Novexel to be Acquired by AstraZeneca
9. AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
10. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary ... included in the Emergency Response Training and Support Services ... excited to have LifeVac become part of the ERTSS ... Founder and CEO of LifeVac. "Having an established network ... and effectively will help leverage our efforts to spread ...
(Date:12/2/2016)... -- PipelineRx, a leading medication management technology company focused ... its SaaS-based telepharmacy platform, PowerGridRx™ , at ... Clinical Meeting and Exhibition, December 5-7 in ... hospital clients nationally, the Company is a leader ... improve pharmacy operations, enhance patient safety, and reduce ...
(Date:12/2/2016)... 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today ... Inc. ("PSI").  The combination of Texas -based ... -based PSI bring together both company,s clinical expertise and high-touch ... an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... years, Doctors on Liens has published a directory of the top doctors working ... When the company started in 1997, the directory was a single page focusing on chiropractors ... directory features a vast array of medical specialists stretching from Sacramento to San ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and ... of those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, ... will give parents and other caregivers the opportunity to share stories and advice, seek ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research ... labeling, storing, shipping and disposal. The new version is a faster and a ...
(Date:12/2/2016)... Wexford, PA (PRWEB) , ... December 02, 2016 , ... ... manages stress and overall health, day and night. No other wearable health technology on ... management. We wanted to give poeple more meaningful insights about their health than ...
Breaking Medicine News(10 mins):